Anavex Life Sciences (AVXL) Net Equity Issued and Repurchased (2010 - 2024)

Anavex Life Sciences has reported Net Equity Issued and Repurchased for 14 years, with the latest figure at $4.1 million in Q2 2024.

• Quarterly Net Equity Issued and Repurchased fell 51.89% year-over-year to $4.1 million in Q2 2024, while the trailing twelve-month figure through Sep 2024 was $13.8 million (down 15.2% YoY) and the FY2024 annual result came in at $11.3 million, down 59.52% from the prior year.
• Net Equity Issued and Repurchased rose to $4.1 million in Q2 2024 per AVXL's latest filing, from $1.2 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $91.3 million in Q2 2021 and troughed at $254.0 in Q3 2021.
• A 5-year average of $14.7 million and a median of $5.9 million in 2020 frame the typical range for Net Equity Issued and Repurchased.
• The sharpest annual moves came in 2021 and 2023: Net Equity Issued and Repurchased tumbled 100.0% in 2021, then jumped 41554.98% in 2023.
• Over 5 years, Net Equity Issued and Repurchased stood at $26.2 million in 2020, then sank by 91.19% to $2.3 million in 2021, then plunged by 99.88% to $2852.0 in 2022, then surged by 41554.98% to $1.2 million in 2023, then soared by 245.62% to $4.1 million in 2024.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $4.1 million, $1.2 million, and $8.5 million for Q2 2024, Q3 2023, and Q2 2023 respectively.